Evidence map›Paper›PMID 41001829›Full record

ArticleThe British journal of dermatology2026

Long-term morbidity and quality of life in survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.

Aaron M Drucker, Elizabeth Williams, Benjamin Kaffenberger, Roni P Dodiuk-Gad, Mary-Margaret Chren, Sharon Phillips, Michelle Martin-Pozo, Michelle S Goh, Elizabeth Ergen, Robert Micheletti and 5 more

Abstract read
In one paragraph

Article in The British journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aaron M DruckerDepartment of Medicine and Research and Innovation Institute, Women's College Hospital, Toronto, ON, Canada.ORCID 0000-0002-7388-9475
Elizabeth WilliamsDepartment of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0009-0000-3648-4033
Benjamin KaffenbergerORCID 0000-0001-8079-0011
Roni P Dodiuk-GadDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-2168-3798
Mary-Margaret ChrenORCID 0000-0001-8009-7014
Sharon PhillipsDepartment of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-4230-4454
Michelle Martin-PozoDepartment of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-1526-9569
Elizabeth Ergen
Robert MichelettiORCID 0000-0003-2517-7008
Alexis YuDepartment of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0009-0003-0775-493X
April O'ConnorDepartment of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0009-0005-8830-8898
Kelby MahanDepartment of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0009-0002-7400-9713
Elizabeth J PhillipsDepartment of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-7623-3383

Funding

NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) 2023R13AR082704 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2023 to 2023
$45k
BMSBoehringer IngelheimDermatology FoundationInflaRxNational Health and Medical Research CouncilNational Psoriasis FoundationNHGRI NIH HHS R01 HG010863NIH HHS R01AI152183NIH HHS R01HG010863NIH HHS R13AR082704NIH HHS RHG010863-01NIH HHS U01AI154659Physicians Services Incorporated Foundation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41001829
PMCPMC12965391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.